We are live on ! Find out more
CLDX icon

Celldex Therapeutics
CLDX

176 hedge funds and large institutions have $2.44B invested in Celldex Therapeutics in 2024 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 68 increasing their positions, 55 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

71% more call options, than puts

Call options by funds: $61.1M | Put options by funds: $35.8M

24% more repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 55

2.74% more ownership

Funds ownership: 105.59% → 108.33% (+2.7%)

3% less funds holding

Funds holding: 182 → 176 (-6)

5% less capital invested

Capital invested by funds: $2.58B → $2.44B (-$135M)

21% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 28

33% less funds holding in top 10

Funds holding in top 10: 6 → 4 (-2)

Holders
176
Holders Change
-6
Holders Change %
-3.3%
% of All Funds
2.53%
Holding in Top 10
4
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-33.33%
% of All Funds
0.06%
New
22
Increased
68
Reduced
55
Closed
28
Calls
$61.1M
Puts
$35.8M
Net Calls
+$25.3M
Net Calls Change
+$39M

Top Buyers

1
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
+$66.1M
2
WP
Woodline Partners
California
+$60.3M
3
Wellington Management Group
Wellington Management Group
Massachusetts
+$44.5M
4
Goldman Sachs
Goldman Sachs
New York
+$36.6M
5
LGM
Logos Global Management
California
+$34.3M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$68.8M
2
Marshall Wace
Marshall Wace
United Kingdom
-$42M
3
SI
Sofinnova Investments
California
-$20.3M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$14.1M
5
PCH
Polar Capital Holdings
United Kingdom
-$13.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
AAA
51
Affinity Asset Advisors
New York
$4.25M -$13.4M -350,400 -74%
PAM
52
Panagora Asset Management
Massachusetts
$3.97M -$63.7K -1,673 -1%
MCP
53
Mirador Capital Partners
California
$3.95M +$144K +3,768 +3%
Swiss National Bank
54
Swiss National Bank
Switzerland
$3.94M +$61K +1,600 +1%
CM
55
Caption Management
Oklahoma
$3.74M +$4.19M +110,000 New
Millennium Management
56
Millennium Management
New York
$3.67M +$2.45M +64,353 +147%
Manulife (Manufacturers Life Insurance)
57
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$3.6M -$915K -24,010 -18%
UBS AM
58
UBS AM
Illinois
$3.49M +$239K +6,269 +7%
RhumbLine Advisers
59
RhumbLine Advisers
Massachusetts
$3.15M -$148K -3,891 -4%
Rafferty Asset Management
60
Rafferty Asset Management
New York
$3.09M -$1.09M -28,504 -24%
Balyasny Asset Management
61
Balyasny Asset Management
Illinois
$2.94M +$3.3M +86,573 New
AGP
62
Artia Global Partners
Florida
$2.56M – – –
Squarepoint
63
Squarepoint
New York
$2.52M -$3.39M -88,997 -55%
Prudential Financial
64
Prudential Financial
New Jersey
$2.33M -$169K -4,430 -6%
AllianceBernstein
65
AllianceBernstein
Tennessee
$2.23M – – –
Susquehanna International Group
66
Susquehanna International Group
Pennsylvania
$2.19M +$639K +16,759 +35%
Canada Pension Plan Investment Board
67
Canada Pension Plan Investment Board
Ontario, Canada
$2.18M +$2.44M +64,000 New
Legal & General Group
68
Legal & General Group
United Kingdom
$2.14M +$177K +4,653 +8%
California State Teachers Retirement System (CalSTRS)
69
California State Teachers Retirement System (CalSTRS)
California
$1.92M -$25K -657 -1%
AG
70
Algert Global
California
$1.87M -$786K -20,631 -27%
State of New Jersey Common Pension Fund D
71
State of New Jersey Common Pension Fund D
New Jersey
$1.79M -$66.1K -1,735 -3%
PHS
72
PFM Health Sciences
California
$1.77M – – –
JP Morgan Chase
73
JP Morgan Chase
New York
$1.73M -$209K -5,489 -10%
Citigroup
74
Citigroup
New York
$1.72M +$970K +25,465 +101%
AA
75
ALPS Advisors
Colorado
$1.72M -$28.3K -742 -1%
1 2
3
4 5

CLDX Hedge Fund Activity: Q3 2024 in Review

176 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q3 2024, worth a combined $2.44B — down 5.2% from $2.58B a quarter earlier.

Sellers outnumbered buyers: 28 funds closed out of CLDX and 22 opened new positions — a net loss of 6 holders — while 55 trimmed existing stakes and 68 added.

The largest buyer was T. Rowe Price Investment Management, opening a new position worth an estimated $66.1M. The largest seller was Fidelity Investments, cutting an estimated $68.8M.

  • 176 institutional investors held Celldex Therapeutics (CLDX) as of Q3 2024, down from 182 in Q2 2024.
  • Funds reported $2.44B of Celldex Therapeutics stock for Q3 2024, down 5.2% quarter-over-quarter.
  • 22 funds opened new Celldex Therapeutics positions in Q3 2024 and 28 closed out, a net change of -6 holders.
  • The largest Celldex Therapeutics buyer in Q3 2024 was T. Rowe Price Investment Management, an estimated $66.1M added.
  • The largest Celldex Therapeutics seller in Q3 2024 was Fidelity Investments, an estimated $68.8M sold.

Based on aggregated 13F filings for Q3 2024.